x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

CRTonline Podcast

Conversations That Inspire

CRTonline Podcast is a collection of interviews with well renowned physicians on medical journals and on-going issues around the world of medicine.

health & fitness medicine

All Episodes

00:20:28

The King and I: Season2, EP 5 - ACC.21 Virtual:...

CRTonline Podcast ·

2021/07/01

Drs. Ron Waksman and Spencer King continue their discussion of late-breaking trials presented at ACC.21 Virtual. This time, they focus on studies of antiplatelet regimens in patients with acute coronary syndrome and antithrombotic regimens after transcatheter aortic valve replacement. They also talk about the frequency (or lack thereof) of updates to guidelines.

en

00:27:16

The King and I: Season2, EP 4 - ACC.21 Virtual:...

CRTonline Podcast ·

2021/07/01

Drs. Ron Waksman and Spencer King discuss the results of late-breaking trials presented at ACC.21 Virtual that report on complete revascularization and physiology. They start with a conversation about when cardiology conferences might be held in person again.

en

00:23:09

The King and I: Season 2, EP 6 - Conflict of interest...

CRTonline Podcast ·

2021/06/22

Drs. Spencer King and Ron Waksman discuss whether authors who involved in developing guidelines should have conflicts of interest with industry. A recent article reported that 80% of European guidelines writers have conflicts. Does this bias guidelines or do these authors have more experience and insights that can strengthen these documents?

en

00:16:45

RESCUE

CRTonline Podcast ·

2021/06/01

Dr. Paul Ridker, of Brigham and Women’s Hospital, Boston, discusses with Dr. Ron Waksman results from the RESCUE trial, which randomized patients at high atherosclerotic risk with stage 3-5 chronic kidney disease to receive ziltivekimab, a novel interleukin-6 ligand inhibitor (7.5 mg, 15 mg or 30 mg) or a placebo. The study, presented as a late-breaking trial at ACC.21 Virtual, found that ziltivekimab markedly reduced multiple biomarkers of systemic inflammation and thrombosis known to promote the

en

00:14:43

REALITY

CRTonline Podcast ·

2021/06/01

Dr. José R. González-Juanatey, of University Hospital, Santiago de Compostela, Spain, discusses with Dr. Ron Waksman results from the REALITY trial, which randomized anemic patients presenting with myocardial infarction to a liberal strategy of red blood cell transfusion or a restrictive strategy. REALITY, which was presented as a late-breaking trial at ACC.21 Virtual, found that the restrictive strategy did not achieve non-inferiority at 1 year after treatment. This was against the pre-study

en

00:14:08

NCDR LAAO Registry

CRTonline Podcast ·

2021/06/01

Dr. Matthew Price, of Scripps Clinic, La Jolla, California, discusses with Dr. Ron Waksman 1-year clinical outcomes after transcatheter left atrial appendage occlusion (LAAO) for stroke prevention in patients with atrial fibrillation (AF). This report from the National Cardiovascular Data Registry (NCDR) LAAO Registry, which was presented as a late-breaking trial at ACC.21 Virtual, found that thromboembolic events were infrequent in patients implanted with the Watchman (Boston Scientific) LAAO

en

00:18:35

SAFE-PAD

CRTonline Podcast ·

2021/05/26

Dr. Eric A. Secemsky, of Beth Israel Lahey Health, Boston, discusses with Dr. Ron Waksman initial results from the SAFE-PAD study, which was presented as a late-breaking trial at ACC.21 Virtual. The observational study found that among more than 160,000 Medicare beneficiaries, in the treatment of peripheral artery disease, paclitaxel-coated devices were non-inferior to non-drug-coated devices with respect to mortality.

en

00:23:08

TWILIGHT: Sex-Specific Outcomes

CRTonline Podcast ·

2021/05/26

Dr. Birgit Vogel, of the Icahn School of Medicine at Mount Sinai, New York, discusses with Dr. Ron Waksman a study examining sex differences in the TWILIGHT trial, which compared patients at high risk of bleeding or ischemic events who received ticagrelor alone vs. those who received ticagrelor plus aspirin after both groups received 3 months of dual antiplatelet therapy post-percutaneous coronary intervention. The study, which was presented as a late-breaking trial at ACC.21 Virtual, found that

en

00:10:37

ISCHEMIA: Completeness of Revascularization – Impact...

CRTonline Podcast ·

2021/05/26

Dr. Kreton Mavromatis, of Emory University and Atlanta VA Medical Center, discusses with Dr. Ron Waksman an analysis of the ISCHEMIA trial evaluating quality of life for patients who underwent complete revascularization with those who underwent more conservative treatment. This analysis, which was presented as a late-breaking trial at ACC.21 Virtual, found that complete revascularization generally resulted in greater improvement in angina-related quality of life than incomplete revascularization,

en

00:19:23

ADAPTABLE

CRTonline Podcast ·

2021/05/25

Dr. William Schuyler Jones, of the Duke Clinical Research Institute, Durham, North Carolina, discusses the ADAPTABLE trial with Dr. Ron Waksman. The study, which was presented as a late-breaking trial at ACC.21 Virtual, found no difference in a composite outcome of death, myocardial infarction or stroke between patients assigned to a low dose (81 mg) vs. a high dose (325 mg) of aspirin with a median 26-month follow-up. Of interest was that patients were recruited and randomized remotely, with no

en

00:17:14

WASE COVID Study: Human vs. Machine-Learning Echo...

CRTonline Podcast ·

2021/05/25

Dr. Federico Asch of MedStar Washington Hospital Center discusses with Dr. Ron Waksman a study comparing the ability of human and artificial intelligence (AI) echocardiography analysis to predict outcomes in acute COVID-19 patients. The study, which was presented as a late-breaking trial at ACC.21 Virtual, found that AI-based analyses of left ventricular ejection fraction and left ventricular longitudinal strain showed a significant decrease in variance and accurately predicted in-hospital and

en

00:16:21

ISCHEMIA: Completeness of Revascularization – Impact...

CRTonline Podcast ·

2021/05/25

Dr. Gregg Stone of Mount Sinai Sinai Health System, New York, discusses with Dr. Ron Waksman an analysis of the ISCHEMIA trial comparing clinical outcomes of patients who underwent complete revascularization with those who underwent more conservative treatment. This analysis, which was presented as a late-breaking trial at ACC.21 Virtual, found that complete revascularization generally resulted in improved outcomes.

en

00:10:33

EBC MAIN

CRTonline Podcast ·

2021/05/21

Dr. David Hildick-Smith, of the Sussex Cardiac Centre, UK, discusses the results of the EBC MAIN study with Dr. Ron Waksman. The study, presented as a late-breaking trial at EuroPCR 2021, suggests no difference in 1-year clinical outcomes of a planned single-stent versus upfront two-stent strategy for true bifurcation distal left main disease.

en

00:12:38

COOL AMI EU

CRTonline Podcast ·

2021/05/21

Dr. Marko Noc, of University Medical Center in Slovenia, discusses the results of the COOL AMI EU pivotal trial with Dr. Ron Waksman. The study, presented as a late-breaking trial at EuroPCR 2021, found longer randomization-to-balloon time and longer total ischemic time, as well as high rates of new-onset paroxysmal atrial fibrillation, for patients who received a therapeutic hypothermia device, the ZOLL Proteus Intra Vascular Temperature Management System, in patients presenting with acute

en

00:18:21

HOST-EXAM

CRTonline Podcast ·

2021/05/21

Dr. Hyo-Soo Kim, of Seoul National University Hospital, discusses the results of the HOST-EXAM trial with Dr. Ron Waksman. The study, presented as a late-breaking trial at ACC.21 Virtual, showed that clopidogrel monotherapy in the chronic maintenance period following percutaneous coronary intervention and 6 to 18 months of dual antiplatelet therapy reduced cardiovascular risk by around 27% compared to aspirin monotherapy.

en

00:12:42

ATLANTIS

CRTonline Podcast ·

2021/05/21

Dr. Gilles Montalescot, of Pitié-Salpêtrière Hospital in Paris, discusses the results of the ATLANTIS trial with Dr. Ron Waksman. The study, presented as a late-breaking trial at ACC.21 Virtual, showed that the blood thinner apixaban was not superior to standard of care following transcatheter aortic valve replacement in terms of net clinical benefits but may remain useful for patients with an indication for oral anticoagulation.

en

00:16:01

TALOS-AMI

CRTonline Podcast ·

2021/05/21

Dr. Kiyuk Chang, from Seoul St. Mary’s Hospital, discusses the results of the TALOS-AMI trial with Dr. Ron Waksman. The study, presented as a late-breaking trial at ACC.21 Virtual, showed that de-escalating stabilized acute myocardial infarction patients from high-potency dual antiplatelet therapy with ticagrelor to a lower-potency option – clopidogrel – 30 days after percutaneous coronary intervention was safer and more effective than continuing on ticagrelor beyond 30 days.

en

00:12:28

FUTURE-II

CRTonline Podcast ·

2021/05/21

Dr. Bo Xu, of the Chinese Academy of Medical Sciences, discusses the results of the FUTURE-II trial with Dr. Ron Waksman. The study, presented as a late-breaking trial at EuroPCR 2021, showed comparable safety and efficacy between the thin-strut Chinese Firesorb bioresorbable vascular scaffold and the cobalt-chromium everolimus-eluting Xience stents

en

00:12:10

Coronary Revascularization vs. Medical Therapy Alone:...

CRTonline Podcast ·

2021/05/21

Dr. Eliano Navarese, of Nicolaus Copernicus University, Poland, discusses the results of a meta-analysis comparing coronary revascularization vs. medical therapy alone. The study, presented as a late-breaking trial at EuroPCR 2021, showed that the benefits of both approaches are additive and that their combination is needed to attain maximal and lasting prevention of adverse events.

en

00:13:27

RADIANCE-HTN TRIO

CRTonline Podcast ·

2021/05/21

Dr. Ajay Kirtane, of Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian/Columbia University Irving Medical Center, discusses the RADIANCE-HTN TRIO trial with Dr. Waksman. The study, presented as a late-breaking trial at ACC.21 Virtual, showed that ultrasound renal denervation, as compared with a sham procedure, reduced blood pressure at 2 months in patients with hypertension resistant to a standardized triple-combination pill.

en

363 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown